Display options
Cite
Pickup JC, Home PD, Bilous RW, et al. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed). 1981;282(6261):347-50doi: 10.1136/bmj.282.6261.347.
Pickup, J. C., Home, P. D., Bilous, R. W., Keen, H., & Alberti, K. G. (1981). Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. British medical journal (Clinical research ed.), 282(6261), 347-50. https://doi.org/10.1136/bmj.282.6261.347
Pickup, J C, et al. "Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption." British medical journal (Clinical research ed.) vol. 282,6261 (1981): 347-50. doi: https://doi.org/10.1136/bmj.282.6261.347
Pickup JC, Home PD, Bilous RW, Keen H, Alberti KG. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed). 1981 Jan 31;282(6261):347-50. doi: 10.1136/bmj.282.6261.347. PMID: 6780019; PMCID: PMC1504135.
Copy Download .nbib Format: NLM
Share it on

Br Med J (Clin Res Ed). 1981 Jan 31;282(6261):347-50. doi: 10.1136/bmj.282.6261.347.

Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.

British medical journal (Clinical research ed.)

J C Pickup, P D Home, R W Bilous, H Keen, K G Alberti

PMID: 6780019 PMCID: PMC1504135 DOI: 10.1136/bmj.282.6261.347

Abstract

Severely brittle diabetes is defined as a rare subtype of insulin-dependent diabetes with wide, fast, unpredictable, and inexplicable swings in blood glucose concentration, often culminating in ketoacidosis or hypoglycaemic coma. To assess the role of inappropriate type, amount, or timing of insulin treatment and the route of administration as a cause of severe brittleness six patients with continuous subcutaneous insulin infusion, which provides a high degree of optimisation of dosage with exogenous insulin in stable diabetics. The glycaemic control achieved during continuous subcutaneous insulin infusion was compared with that during continuous intramuscular insulin infusion. Six patients with non-brittle diabetes were also treated by continuous subcutaneous insulin infusion. These patients achieved the expected improvement in glycaemic control (mean +/- SD plasma glucose concentration 5.1 +/- 2.3 mmol/l (92 +/- 41 mg/100 ml)), but not the patients with brittle diabetes remained uncontrolled with continuous subcutaneous infusion (13.6 +/- 5.8 mmol/1 (245 +/- 105 mg/100 ml) compared with 10.3 +/- 4.1 mmol/l (186 +/- 74 mg/100 ml) during treatment with optimised conventional subcutaneous injections). During continuous intramuscular infusion, however, glycaemic control in five of the patients with brittle diabetes was significantly improved (7.7 +/- 2.6 mmol/l (139 +/- 47 mg/100 ml). The remaining patient with brittle diabetes, previously safely controlled only with continuous intravenous insulin, did not respond to continuous intramuscular infusion. It is concluded that in five of the six patients with brittle diabetes studied here impaired or irregular absorption of insulin from the subcutaneous site played a more important part in their hyperlability than inappropriate injection strategies. This absorption defect was presumably bypassed by the intramuscular route.

Cited by

References

  1. Br Med J. 1978 Jan 28;1(6107):204-7 - PubMed
  2. Clin Endocrinol Metab. 1977 Jul;6(2):403-19 - PubMed
  3. Lancet. 1980 Jul 12;2(8185):93-4 - PubMed
  4. Diabetes Care. 1980 Mar-Apr;3(2):290-300 - PubMed
  5. Lancet. 1978 Sep 30;2(8092 Pt 1):741 - PubMed
  6. Can Med Assoc J. 1964 Apr 18;90:953-9 - PubMed
  7. N Engl J Med. 1979 Mar 15;300(11):573-8 - PubMed
  8. Diabetes. 1979 Jul;28(7):640-5 - PubMed
  9. Lancet. 1979 Jun 16;1(8129):1255-7 - PubMed
  10. Lancet. 1979 Jun 16;1(8129):1258-61 - PubMed
  11. Diabetologia. 1979 Jun;16(6):385-9 - PubMed
  12. Diabetologia. 1979 Aug;17(2):97-9 - PubMed
  13. Lancet. 1979 Oct 27;2(8148):870-3 - PubMed
  14. Am J Med. 1980 Feb;68(2):190-6 - PubMed
  15. Diabetologia. 1980 Jan;18(1):1-4 - PubMed
  16. Aust N Z J Med. 1980 Feb;10(1):56-61 - PubMed
  17. Diabetes. 1980 Jan;29(1):81-3 - PubMed
  18. Diabetes. 1980 Mar;29(3):206-12 - PubMed
  19. Lancet. 1978 Aug 5;2(8084):283-5 - PubMed

Substances

MeSH terms

Publication Types